Literature DB >> 7737578

New salicylates as maintenance treatment in ulcerative colitis.

C A Sninsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7737578      PMCID： PMC1382514          DOI： 10.1136/gut.36.4.640

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  5 in total

1.  Comparisons of olsalazine and mesalazine in prevention of relapse in ulcerative colitis.

Authors:  J E Gait; N A Simerl
Journal:  Lancet       Date:  1992-08-22       Impact factor: 79.321

2.  Mesalazine versus olsalazine for prophylaxis of ulcerative colitis relapse.

Authors:  C O Record; K Macrae
Journal:  Lancet       Date:  1992-12-12       Impact factor: 79.321

3.  Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis.

Authors:  L R Sutherland; G R May; E A Shaffer
Journal:  Ann Intern Med       Date:  1993-04-01       Impact factor: 25.391

4.  Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.

Authors:  M G Courtney; D P Nunes; C F Bergin; M O'Driscoll; V Trimble; P W Keeling; D G Weir
Journal:  Lancet       Date:  1992-05-23       Impact factor: 79.321

5.  Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

Authors:  C A Sninsky; D H Cort; F Shanahan; B J Powers; J T Sessions; R E Pruitt; W H Jacobs; S K Lo; S R Targan; J J Cerda
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.